ATE531711T1 - Für die behandlung von autoimmunerkrankungen und entzündlichen erkrankungen geeignete tetrahydrocyclopentaäbüindol-3- ylcarbonsäurederivate - Google Patents

Für die behandlung von autoimmunerkrankungen und entzündlichen erkrankungen geeignete tetrahydrocyclopentaäbüindol-3- ylcarbonsäurederivate

Info

Publication number: ATE531711T1
Authority: AT; Austria
Prior art keywords: diseases; treatment; acid derivatives; tetrahydrocyclopentaäbüindol; carbonic acid
Prior art date: 2007-12-18

Application number

AT08861137T

Other languages

English (en)

Inventor

Robert Jones

Daniel Buzard

Andrew Kawasaki

Luis Lopez

Jeanne Moody

Lars THORESEN

Brett Ullman

Original Assignee

Arena Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-12-18

Filing date

2008-12-15

Publication date

2011-11-15

2008-12-15 Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc

2011-11-15 Application granted granted Critical

2011-11-15 Publication of ATE531711T1 publication Critical patent/ATE531711T1/de

Links

208000023275 Autoimmune disease Diseases 0.000 title 1
208000037979 autoimmune inflammatory disease Diseases 0.000 title 1
150000004649 carbonic acid derivatives Chemical class 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
150000001875 compounds Chemical class 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
SPDCGFKWKYRIIU-UHFFFAOYSA-N 1-(1,2,4-oxadiazol-3-yl)-1,2,3,4-tetrahydrocyclopenta[b]indole-3-carboxylic acid Chemical class N1C2=CC=CC=C2C2=C1C(C(=O)O)CC2C=1N=CON=1 SPDCGFKWKYRIIU-UHFFFAOYSA-N 0.000 abstract 1
208000002874 Acne Vulgaris Diseases 0.000 abstract 1
206010009900 Colitis ulcerative Diseases 0.000 abstract 1
208000011231 Crohn disease Diseases 0.000 abstract 1
201000004681 Psoriasis Diseases 0.000 abstract 1
102100025750 Sphingosine 1-phosphate receptor 1 Human genes 0.000 abstract 1
101710155454 Sphingosine 1-phosphate receptor 1 Proteins 0.000 abstract 1
102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 abstract 1
108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 abstract 1
206010052779 Transplant rejections Diseases 0.000 abstract 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
208000036142 Viral infection Diseases 0.000 abstract 1
206010000496 acne Diseases 0.000 abstract 1
239000000556 agonist Substances 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
230000000813 microbial effect Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
201000006417 multiple sclerosis Diseases 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000000144 pharmacologic effect Effects 0.000 abstract 1
206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
230000009385 viral infection Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Oncology (AREA)
Diabetes (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Virology (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Transplantation (AREA)
Psychiatry (AREA)
Obesity (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)

AT08861137T 2007-12-18 2008-12-15 Für die behandlung von autoimmunerkrankungen und entzündlichen erkrankungen geeignete tetrahydrocyclopentaäbüindol-3- ylcarbonsäurederivate ATE531711T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US807907P	2007-12-18	2007-12-18
PCT/US2008/013753 WO2009078983A1 (en)	2007-12-18	2008-12-15	Tetrahydrocyclopenta[b]indol-3-yl carboxylic acid derivatives useful in the treatment of autoimmune and inflammatory disorders

Publications (1)

Publication Number	Publication Date
ATE531711T1 true ATE531711T1 (de)	2011-11-15

Family

ID=40383785

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT08861137T ATE531711T1 (de)	2007-12-18	2008-12-15	Für die behandlung von autoimmunerkrankungen und entzündlichen erkrankungen geeignete tetrahydrocyclopentaäbüindol-3- ylcarbonsäurederivate

Country Status (8)

Country	Link
US (1)	US20100273806A1 (de)
EP (1)	EP2222668B1 (de)
JP (1)	JP2011506600A (de)
CN (1)	CN101945862A (de)
AT (1)	ATE531711T1 (de)
AU (1)	AU2008338965A1 (de)
CA (1)	CA2707513A1 (de)
WO (1)	WO2009078983A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8853392B2 (en)	2007-06-03	2014-10-07	Vanderbilt University	Benzamide mGluR5 positive allosteric modulators and methods of making and using same
US8034806B2 (en)	2007-11-02	2011-10-11	Vanderbilt University	Bicyclic mGluR5 positive allosteric modulators and methods of making and using same
WO2009094157A1 (en) *	2008-01-25	2009-07-30	Arena Pharmaceuticals, Inc.	Dihydro- 1h- pyrrolo [1,2-a] indol-1-yl carboxylic derivatives which act as s1p1 agonists
WO2009151626A1 (en) *	2008-06-13	2009-12-17	Arena Pharmaceuticals, Inc.	Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists
WO2009151621A1 (en) *	2008-06-13	2009-12-17	Arena Pharmaceuticals, Inc.	Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists
CN104311472B9 (zh) *	2008-07-23	2020-03-17	艾尼纳制药公司	经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物
PL2342205T4 (pl) *	2008-08-27	2016-12-30		Podstawione tricykliczne pochodne kwasowe jako antagoniści receptora S1P1 użyteczni w leczeniu zaburzeń autoimmunologicznych i zapalnych
JP5391372B2 (ja) *	2009-07-08	2014-01-15	公益財団法人名古屋産業科学研究所	芳香族アミン化合物の製造方法
AU2010319879A1 (en)	2009-10-29	2012-06-14	Bristol-Myers Squibb Company	Tricyclic heterocyclic compounds
CA2780859A1 (en) *	2009-12-10	2011-06-16	Novartis Ag	Fty720 halogenated derivatives
EP2528894A1 (de) *	2010-01-27	2012-12-05	Arena Pharmaceuticals, Inc.	Verfahren zur herstellung von (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)essigsäure und salzen daraus
CN105503882B (zh)	2010-03-03	2019-07-05	艾尼纳制药公司	制备s1p1受体调节剂及其晶体形式的方法
CA2818470C (en) *	2011-01-19	2019-03-05	Actelion Pharmaceuticals Ltd	2-methoxy-pyridin-4-yl derivatives
WO2012109749A1 (en) *	2011-02-14	2012-08-23	The Governors Of The University Of Alberta	Boronic acid catalysts and methods of use thereof for activation and transformation of carboxylic acids
CN103058870A (zh) *	2013-01-14	2013-04-24	中国药科大学	一种2-氧代环戊基乙酸乙酯的制备方法
CA3002540C (en)	2015-01-06	2023-11-07	Arena Pharmaceuticals, Inc.	Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
JP6838744B2 (ja)	2015-06-22	2021-03-03	アリーナファーマシューティカルズ，インコーポレイテッド	Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
TWI757266B (zh) *	2016-01-29	2022-03-11	美商維它藥物有限責任公司	ＲＯＲ－γ調節劑
KR102482825B1 (ko)	2016-09-02	2022-12-29	브리스톨-마이어스 스큅 컴퍼니	치환된 트리시클릭 헤테로시클릭 화합물
KR20190113955A (ko)	2017-02-16	2019-10-08	아레나 파마슈티칼스, 인크.	장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법
CN110520124A (zh)	2017-02-16	2019-11-29	艾尼纳制药公司	用于治疗原发性胆汁性胆管炎的化合物和方法
US11046646B2 (en)	2017-08-09	2021-06-29	Bristol-Myers Squibb Company	Alkylphenyl compounds
US11059784B2 (en)	2017-08-09	2021-07-13	Bristol-Myers Squibb Company	Oxime ether compounds
JP7397011B2 (ja)	2018-06-06	2023-12-12	アリーナファーマシューティカルズ，インコーポレイテッド	Ｓ１ｐ１受容体に関連する状態を治療する方法
EP3847158B1 (de)	2018-09-06	2026-06-24	Arena Pharmaceuticals, Inc.	Verbindungen zur behandlung von autoimmun- und entzündungserkrankungen
CN111518091B (zh) *	2020-04-22	2023-02-03	安徽医科大学	一种1，2，4-噁二唑并吡啶类化合物ahmu07及其作为抗菌药物的应用
CN112812052B (zh) *	2021-02-02	2023-12-01	成都阿奇生物医药科技有限公司	一种治疗溃疡性结肠炎的化合物及其制备方法和用途
CN115260173B (zh) *	2021-04-30	2024-08-30	厦门宝太生物科技股份有限公司	环戊烷并吲哚类支链酸衍生物及其制备方法和应用
US20240252665A1 (en) *	2021-06-02	2024-08-01	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	Chemical coupling linker and use thereof
CN116836157A (zh) *	2022-03-25	2023-10-03	星希尔生物科技(上海)有限公司	一种噁二唑衍生物及其制备方法和用途
CN121548565A (zh) *	2023-07-05	2026-02-17	苏州湃芮生物科技有限公司	一种吲哚类化合物及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5830911A (en) *	1996-08-14	1998-11-03	American Home Products Corporation	Pyranoindole and tetrahydrocarbazole inhibitors of COX-2
WO2005032465A2 (en) *	2003-10-01	2005-04-14	Merck & Co., Inc.	3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
EP2003132B1 (de) *	2006-04-03	2014-03-05	Astellas Pharma Inc.	Oxadiazolderivate als S1P1-Agonisten
CA2684385A1 (en) *	2007-04-19	2008-10-30	Glaxo Group Limited	Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists
WO2009094157A1 (en) *	2008-01-25	2009-07-30	Arena Pharmaceuticals, Inc.	Dihydro- 1h- pyrrolo [1,2-a] indol-1-yl carboxylic derivatives which act as s1p1 agonists
CN104311472B9 (zh) *	2008-07-23	2020-03-17	艾尼纳制药公司	经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物

2008
- 2008-12-15 US US12/808,872 patent/US20100273806A1/en not_active Abandoned
- 2008-12-15 EP EP08861137A patent/EP2222668B1/de active Active
- 2008-12-15 AU AU2008338965A patent/AU2008338965A1/en not_active Abandoned
- 2008-12-15 CN CN2008801270087A patent/CN101945862A/zh active Pending
- 2008-12-15 CA CA2707513A patent/CA2707513A1/en not_active Abandoned
- 2008-12-15 AT AT08861137T patent/ATE531711T1/de active
- 2008-12-15 WO PCT/US2008/013753 patent/WO2009078983A1/en not_active Ceased
- 2008-12-15 JP JP2010539452A patent/JP2011506600A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
CN101945862A (zh)	2011-01-12
US20100273806A1 (en)	2010-10-28
JP2011506600A (ja)	2011-03-03
WO2009078983A1 (en)	2009-06-25
CA2707513A1 (en)	2009-06-25
EP2222668A1 (de)	2010-09-01
AU2008338965A1 (en)	2009-06-25
EP2222668B1 (de)	2011-11-02

Publication	Publication Date	Title
MX354134B (es)	2018-02-14	Derivados de acido 1,2,3,4-tetrahidrociclopenta [b] indol-3-il) acetico sustituidos utiles en el tratamiento de enfermedades autoinmune e inflamatorias.
EP3416948B1 (de)	2024-07-24	Indazen aufweisende sulfonylharnstoffe als entzündungshemmstoffe
CY1117830T1 (el)	2017-05-17	Υποκατεστημενα παραγωγα τρικυκλικων οξεων ως αγωνιστες του υποδοχεα s1p1 χρησιμα στην αγωγη αυτοανοσων και φλεγμονοδων διαταραχων
MA32898B1 (fr)	2011-12-01	Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone
AU2003235259B2 (en)	2008-10-16	Benzimidazole derivatives
BRPI0406762A (pt)	2005-12-20	Derivados de n-(1-benzil-2-oxo-2-(1-piperazinil)etil)-1-piperidincarb oxamida e compostos relacionados como antagonistas de cgrp, para tratamento de dores de cabeça
MX2010003346A (es)	2010-04-09	Piperazino-dihidrotienopirimidinas sustituidas en heterociclo.
NO20083500L (no)	2008-09-02	1,4-disubstituerte 3-cyano-pyridonderivater og deres anvendelse som positiv-allosteriske modulatorer av mGluR2 receptorer
MA33450B1 (fr)	2012-07-03	Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques
MX2012004848A (es)	2012-05-29	Compuestos heterociclicos triciclicos.
NZ605431A (en)	2015-06-26	D2 antagonists, methods of synthesis and methods of use
CY1111429T1 (el)	2015-08-05	1,3-διυποκατεστημενα αμιδια 4-μεθυλο-1η-πυρρολο-2-καρβονικου οξεος και η χρησιμοποιηση τους για την παρασκευη φαρμακων
SA515370035B1 (ar)	2018-01-04	مركبات فينوكسي إيثيل داي هيدرو-‏‎1h‎‏-أيزوكوينولين
EA200801184A1 (ru)	2008-08-29	Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2
IL202236A0 (en)	2010-06-16	Prolinamide derivatives as nk3 antagonists
MA33417B1 (fr)	2012-07-03	Compositions pharmaceutiques et formes solides
RU2014149123A (ru)	2016-08-20	Фенилтриазольное производное и его применение для модуляции ГАМКА-рецепторного комплекса
EA200970553A1 (ru)	2009-10-30	Пиперидиниламинопиридазины и их применение в качестве быстро диссоциирующих антагонистов рецептора допамина 2
SG158924A1 (en)	2010-02-26	Modulators of chemokine receptor activity, crystalline forms and process
CA2990028A1 (en)	2015-12-30	Enzyme interacting agents
DE602008005014D1 (de)	2011-03-31	Prolinamidtetrazolderivate als nk3-rezeptorantagonisten
BRPI0512404A (pt)	2008-03-04	inibidores de mao-b
TW201144311A (en)	2011-12-16	Azaisoquionolinone derivatives as NK3 antagonists
TH137350A (th)	2014-10-17	แอริลเมทธิลเบนโซควินาโซลิโนน สารปรับควบคุมอัลโลสเตอริกแบบบวกของ m1 รีเซพเตอร์
TH106465A (th)	2011-03-15	โดพามีน 2 รีเซพเทอร์แอนทาโกนิสท์ที่แยกออกได้เร็ว